Overexpression of HCC1/CAPERα may play a role in lung cancer carcinogenesis
- PMID: 24643682
- PMCID: PMC4110178
- DOI: 10.1007/s13277-014-1819-y
Overexpression of HCC1/CAPERα may play a role in lung cancer carcinogenesis
Abstract
HCC1/CAPERα is considered to be a novel human tumor-associated antigen, and the tumor-specific immunity of HCC1/CAPERα has been reported in several types of cancer. However, there was very limited evidence indicating its function in tumorigenesis. In the present study, to elucidate the roles and underlying molecular mechanism of HCC1/CAPERα in lung cancer, we examined the expression of HCC1/CAPERα in human non-small cell lung cancer (NSCLC) cell line and NSCLC tissue microarray (TMA). Immunohistochemistry with TMA was performed to detect HCC1/CAPERα expression in NSCLC and adjacent lung tissues. NSCLC cell line constitutively transfected by pcDNA3.1-HCC1/CAPERα, and empty pcDNA3.1 vector were used. These cells were analyzed by Western blot, MTT, immunofluorescence, wound healing assay, and transwell assays. It was found that HCC1/CAPERα was mainly localized in the nucleus of the lung cancer cells and overexpression of HCC1/CAPERα may promote lung cancer cells proliferation and increase cells migration. The frequency of HCC1/CAPERα expression in NSCLC tissues was significantly higher than that in adjacent and normal tissues (P < 0.01). Our data suggest that overexpression of HCC1/CAPERα may increase the proliferation and migration of NSCLC cells, and HCC1/CAPERα could be a promising biomarker for lung cancer.
Conflict of interest statement
Conflicts of interest None
Figures




Similar articles
-
Phosphatidylethanolamine-binding protein 4 promotes the epithelial-to-mesenchymal transition in non-small cell lung cancer cells by activating the sonic hedgehog signaling pathway.J Cell Biochem. 2019 Apr;120(4):5386-5395. doi: 10.1002/jcb.27817. Epub 2018 Oct 26. J Cell Biochem. 2019. PMID: 30367510
-
PHB2 promotes tumorigenesis via RACK1 in non-small cell lung cancer.Theranostics. 2021 Jan 1;11(7):3150-3166. doi: 10.7150/thno.52848. eCollection 2021. Theranostics. 2021. PMID: 33537079 Free PMC article.
-
UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC.Theranostics. 2019 Mar 17;9(7):2036-2055. doi: 10.7150/thno.32738. eCollection 2019. Theranostics. 2019. Retraction in: Theranostics. 2020 Jul 25;10(21):9619. doi: 10.7150/thno.50254. PMID: 31037155 Free PMC article. Retracted.
-
ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.Theranostics. 2021 Jan 19;11(7):3392-3416. doi: 10.7150/thno.52435. eCollection 2021. Theranostics. 2021. PMID: 33537094 Free PMC article.
-
lncRNA BCAR4 Increases Viability, Invasion, and Migration of Non-Small Cell Lung Cancer Cells by Targeting Glioma-Associated Oncogene 2 (GLI2).Oncol Res. 2019 Feb 21;27(3):359-369. doi: 10.3727/096504018X15220594629967. Epub 2018 Apr 3. Oncol Res. 2019. PMID: 29615150 Free PMC article.
Cited by
-
Recent advances in anticancer mechanisms of molecular glue degraders: focus on RBM39-dgrading synthetic sulfonamide such as indisulam, E7820, tasisulam, and chloroquinoxaline sulfonamide.Genes Genomics. 2024 Dec;46(12):1345-1361. doi: 10.1007/s13258-024-01565-z. Epub 2024 Sep 13. Genes Genomics. 2024. PMID: 39271535 Review.
-
Systematic pan-cancer analysis identifies RBM39 as an immunological and prognostic biomarker.J Cell Mol Med. 2022 Sep;26(18):4859-4871. doi: 10.1111/jcmm.17517. Epub 2022 Aug 21. J Cell Mol Med. 2022. PMID: 35989423 Free PMC article.
-
The Role of RNA-Binding Proteins in Hematological Malignancies.Int J Mol Sci. 2022 Aug 23;23(17):9552. doi: 10.3390/ijms23179552. Int J Mol Sci. 2022. PMID: 36076951 Free PMC article. Review.
-
Using recursive partitioning approach to select tumor-associated antigens in immunodiagnosis of gastric adenocarcinoma.Cancer Sci. 2019 Jun;110(6):1829-1841. doi: 10.1111/cas.14013. Epub 2019 May 7. Cancer Sci. 2019. PMID: 30950146 Free PMC article.
-
RNA-binding protein 39: a promising therapeutic target for cancer.Cell Death Discov. 2021 Aug 13;7(1):214. doi: 10.1038/s41420-021-00598-7. Cell Death Discov. 2021. PMID: 34389703 Free PMC article. Review.
References
-
- Tan HT, Lee YH, Chung MC. Cancer proteomics. Mass Spectrom Rev. 2012;31:583–605. - PubMed
-
- Soussi T. P53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 2000;60:1777–88. - PubMed
-
- Looi K, Megliorino R, Shi FD, Peng XX, Chen Y, Zhang JY. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Onco Rep. 2006;16:1105–10. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources